Shopping Cart 0
Cart Subtotal
AED 0

Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 31177

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 62353

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 93530
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026

Summary

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of non-alcoholic fatty liver disease (NAFLD). NASH is becoming increasingly common with the alarming epidemic of obesity and carries the risk for more aggressive liver diseases such as cirrhosis, liver failure, and in some rare instances, hepatocellular cancer.

Therapeutic options for NASH are currently very limited, with Vitamin E being the standard of care for patients. This leaves significant unmet need for the disease and, coupled with high disease prevalence in developed countries, results in enticing opportunities for drug developers. As such, there is a very active pipeline for NASH, and many new products are expected to launch over the next 10 years. However, there is still uncertainty over how the NASH treatment landscape will develop as these new products launch.

Key Questions Answered

- The NASH market is poised to undergo rapid expansion during the forecast period and beyond. What are the main drivers of this expansion?

- What are the main unmet needs in NASH? Will the drugs under development fulfil these needs?

- Which patients are the most likely to receive drug treatment for NASH during the forecast period, and which patients are unlikely to be reimbursed?

Scope

Components of the slide deck include-

- Timeline of market-impacting events

- Key clinical trial landscape updates

- Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective

- Overview of updates to the forecast model based on anticipated future impact of events

- Forward-looking events calendar listing expected key updates to the NASH competitive space through September 2019

Other events included in the analysis include-

- Regulatory filings

- Approval decisions

- Pricing changes

- Patent litigation

- Clinical trial data announcements

- Clinical trial failures

- Clinical trial timeline updates.

Reasons to buy

The report will enable you to-

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global NASH therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NASH therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

READ MORE

Table Of Content

Scope

Table of Contents

1. Dynamic Market Forecast Overview 5

1.1 Related Reports 6

1.2 Upcoming Related Reports 7

2. Executive Summary 8

2.1 Key Updates to NASH Market Dynamics 9

2.2 Key Events in Update 10-12

2.3 Clinical Trial Landscape Updates 13-14

2.4 Competitive Assessment of Late-Stage Pipeline 15

2.5 Market Insight on Key Events 16

3. Event 1: Increased Understanding of Potential Treatment Algorithms for NASH Patients With Cirrhosis 17

3.1 Key Event Updates 18

3.2 Competitive Landscape of Drugs Targeting NASH F4 Patients 19

3.3 New Pricing Model to Differentiate Between Patient Segments 20

3.4 Increased competition in the NASH Pipeline Within the F4 Patient Segment 21

3.5 What Do Physicians Think? 22

3.6 Summary 23

3.7 Sources 24

4. Event 2: First Publication of Efficacy Data for Certain Phase II NASH Drugs 25

4.1 Key Event Updates 26

4.2 Competitive Landscape of New Drugs added to Forecast 27

4.3 Four Phase II Drugs Shown to Lower Liver Fat Content 28-29

4.4 Summary 30

4.5 Sources 31

5. Event 3: Combination Therapies for NASH 32

5.1 Key Event Updates 33

5.2 Gilead Shifts NASH Strategy Towards Combination Therapies 34

5.3 What Do Physicians Think 35

5.4 Summary 36

5.5 Sources 37

6. Event 4: Publication of New Phase II Efficacy Data Shifts Competitive Landscape for NASH Pipeline 38

6.1 Key Event Updates 39

6.2 Cenicriviroc and IMM-124E Supported by More Positive Phase II Data 40

6.3 Poor Phase IIb Efficacy results for Galmed's Aramchol 41

6.4 Competitive Landscape of Drugs With Recently Published Efficacy Data 42

6.5 Summary 43

6.6 Sources 44

7. Events Calendar 45

7.1 Key Events Expected to Occur in October 2018-September 2019 46

8. Appendix 47

8.1 Methodology 48

8.2 Primary Research 49-50

8.3 About the Authors 51-53

8.4 About GlobalData 54

8.5 Contact Us 55

8.6 Disclaimer 56

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Allergan

Cirius Therapeutics

Conatus Pharma

Galectin Therapeutics

Galmed Pharmaceuticals

Genfit

Gilead Sciences

Immuron

Intercept Pharmaceuticals

Inventiva

Madrigal Pharmaceuticals

Mitsubishi Tanabe

NGM Bio

Novartis

Novo Nordisk

Viking Therapeutics

Non-Alcoholic Steatohepatitis (NASH): Dynamic Market Forecast to 2026

Summary

Non-alcoholic steatohepatitis (NASH) is a common, often clinically silent liver disease characterized by the presence of a fatty, inflamed, and damaged liver. It resembles alcoholic liver disease but occurs in people who drink little or no alcohol, and is a highly progressed form of non-alcoholic fatty liver disease (NAFLD). NASH is becoming increasingly common with the alarming epidemic of obesity and carries the risk for more aggressive liver diseases such as cirrhosis, liver failure, and in some rare instances, hepatocellular cancer.

Therapeutic options for NASH are currently very limited, with Vitamin E being the standard of care for patients. This leaves significant unmet need for the disease and, coupled with high disease prevalence in developed countries, results in enticing opportunities for drug developers. As such, there is a very active pipeline for NASH, and many new products are expected to launch over the next 10 years. However, there is still uncertainty over how the NASH treatment landscape will develop as these new products launch.

Key Questions Answered

- The NASH market is poised to undergo rapid expansion during the forecast period and beyond. What are the main drivers of this expansion?

- What are the main unmet needs in NASH? Will the drugs under development fulfil these needs?

- Which patients are the most likely to receive drug treatment for NASH during the forecast period, and which patients are unlikely to be reimbursed?

Scope

Components of the slide deck include-

- Timeline of market-impacting events

- Key clinical trial landscape updates

- Detailed analysis of the most impactful events, including new primary research to gain Key Opinion Leader perspective

- Overview of updates to the forecast model based on anticipated future impact of events

- Forward-looking events calendar listing expected key updates to the NASH competitive space through September 2019

Other events included in the analysis include-

- Regulatory filings

- Approval decisions

- Pricing changes

- Patent litigation

- Clinical trial data announcements

- Clinical trial failures

- Clinical trial timeline updates.

Reasons to buy

The report will enable you to-

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global NASH therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global NASH therapeutics market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

READ MORE

Scope

Table of Contents

1. Dynamic Market Forecast Overview 5

1.1 Related Reports 6

1.2 Upcoming Related Reports 7

2. Executive Summary 8

2.1 Key Updates to NASH Market Dynamics 9

2.2 Key Events in Update 10-12

2.3 Clinical Trial Landscape Updates 13-14

2.4 Competitive Assessment of Late-Stage Pipeline 15

2.5 Market Insight on Key Events 16

3. Event 1: Increased Understanding of Potential Treatment Algorithms for NASH Patients With Cirrhosis 17

3.1 Key Event Updates 18

3.2 Competitive Landscape of Drugs Targeting NASH F4 Patients 19

3.3 New Pricing Model to Differentiate Between Patient Segments 20

3.4 Increased competition in the NASH Pipeline Within the F4 Patient Segment 21

3.5 What Do Physicians Think? 22

3.6 Summary 23

3.7 Sources 24

4. Event 2: First Publication of Efficacy Data for Certain Phase II NASH Drugs 25

4.1 Key Event Updates 26

4.2 Competitive Landscape of New Drugs added to Forecast 27

4.3 Four Phase II Drugs Shown to Lower Liver Fat Content 28-29

4.4 Summary 30

4.5 Sources 31

5. Event 3: Combination Therapies for NASH 32

5.1 Key Event Updates 33

5.2 Gilead Shifts NASH Strategy Towards Combination Therapies 34

5.3 What Do Physicians Think 35

5.4 Summary 36

5.5 Sources 37

6. Event 4: Publication of New Phase II Efficacy Data Shifts Competitive Landscape for NASH Pipeline 38

6.1 Key Event Updates 39

6.2 Cenicriviroc and IMM-124E Supported by More Positive Phase II Data 40

6.3 Poor Phase IIb Efficacy results for Galmed's Aramchol 41

6.4 Competitive Landscape of Drugs With Recently Published Efficacy Data 42

6.5 Summary 43

6.6 Sources 44

7. Events Calendar 45

7.1 Key Events Expected to Occur in October 2018-September 2019 46

8. Appendix 47

8.1 Methodology 48

8.2 Primary Research 49-50

8.3 About the Authors 51-53

8.4 About GlobalData 54

8.5 Contact Us 55

8.6 Disclaimer 56

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Allergan

Cirius Therapeutics

Conatus Pharma

Galectin Therapeutics

Galmed Pharmaceuticals

Genfit

Gilead Sciences

Immuron

Intercept Pharmaceuticals

Inventiva

Madrigal Pharmaceuticals

Mitsubishi Tanabe

NGM Bio

Novartis

Novo Nordisk

Viking Therapeutics